Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 33, 2003 - Issue 4
76
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Pharmacokinetics, metabolism and excretion of the glycine antagonist GV150526A in rat and dog

, , , , , & show all
Pages 415-428 | Published online: 22 Sep 2008

References

  • DI FABIO, R., CAPELLI, A. M., CONTI, N., CUGOLA, A., DONATI, D., FERIANI, A., GASTALDI, P., GAVIRAGHI, G., HEWKIN, C. T., MICHELI, F., Missio, A., MUGNAINI, M., PECUNIOSO, A., QUAGLIA, A. M., RATTI, E., Rossi, L., TEDESCO, G., TRIST, D. G. and REGGIANI, A., 1997, Substituted indole-2—carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. Journal of Medicinal Chemistry, 40, 841–850.
  • DI FABIO, R., CUGOLA, A., DONATI, D., FERIANI, A., GAVIRAGHI, G., RATTI, E., TRIST, D. G and REGGIANI, A., 1998, Identification and pharmacological characterization of GV150526, a novel glycine antagonist as a potent neuroprotective agent, Drugs of the Future, 23, 61–69.
  • FAED, E. M., 1984, Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metabolism Reviews, 15, 1213–1249.
  • GAVIRAGHI, G., DI FABIO, R., CUGOLA, A., DONATI, D., FERIANI, A., RATTI, E., TRIST, D. G. and REGGIANI, A., 1997, Novel glycine antagonists as neuroprotective agents. In Proceedings of the XIVth International Symposium on Medicinal Chemistry (Amsterdam: Elsevier), 28, pp. 81–95.
  • GILISSEN, R. A. H., FERRARI, L., BARNABY, R. J. and KAJBAF, M., 2000, Human hepatic metabolism of a novel 2-carboxyindole glycine antagonist for stroke: in-vitro—in-vivo correlations. Xenobiotica, 30, 843–856.
  • HASEGAWA, J., SMITH, P. and BENET, L. Z., 1982, Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metabolism and Disposition, 10, 469–473.
  • HOKE, J. F., DYKER, A. G., BARNABY, R. J. and LEES, K. R., 2000, Pharmacokinetics of GV150526 following multiple dosing in patients with acute stroke. European Journal of Clinical Pharmacology, 5, 867–872.
  • IAVARONE, L., HOKE, J. F., BOTTACINI, M., BARNABY, R. J. and PRESTON, G. C., 1999, First time in human for GV19677: Interspecies scaling applied on dose selection. Journal of Clinical Pharmacology, 39, 560–566.
  • LENZ, E. M., GREATBANKS, D., WILSON, I., SPRAUL, M., HOFMANN, M., TROKE, J., LINDON, J. and NICHOLSON, J. K., 1996, Direct Characterisation of drug glucuronide isomers in human urine by HPLC-NMR. Analytical Chemistry, 68, 2832–2837.
  • McGurix, K. A., REMMEL, R. P., HOSAGRAHARA, V. P., Tosx, D. and BURCHELL, B., 1996, Reactivity of mefenamic acid 1-0-acyl glucuronide with proteins in-vitro and ex-vivo. Drug Metabolism and Disposition, 24, 842–849.
  • Qiu, Y., BURLINGAME, A. L. and BENET, L. Z., 1997, Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Drug Metabolism and Disposition, 26, 246–256.
  • REGGIANI, A., 1997, Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. Journal of Medicinal Chemistry, 40, 841–850.
  • SALMON, M., FENSELAU, C., CUKIER, J. 0. and ODELL, G. B., 1974, Rapid transesterification of bilirubin glucuronides in methanol. Life Sciences, 15, 2069–2078.
  • SIDELMANN, U. G., LENZ, E., SPRAUL, M., HOMANN, M., TROKE, J., SANDERSON, P. N., LINDON, J. C., WILSON, I. D. and NICHOLSON, J. K., 1996,750 MHz HPLC-NMR spectroscopic studies on the separation and characterisation of the positional isomers of the glucuronides of dihydro oxodibenzoxepin acetic acid. Analytical Chemistry, 68, 106–110.
  • SPAHN-LANGGUTH, H. and BENET, L. Z., 1992, Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism. Drug Metabolism Reviews, 24, 5–48.
  • WANG, M. and DICKINSON, R. G., 1997, Disposition and covalent binding of difiunisal and difiunisal acyl glucuronide in the isolated perfused rat liver. Drug Metabolism and Disposition, 26, 98–104.
  • ZIVIN, J. A., 1997, Neurprotective therapies in stroke. Drugs, 54, 83–89.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.